|Maryam Ahmadi||Managing Director||PH.D.||Medical Biotechnology||Semnan University of Medical Sciences|
|Samira Ahmadi||The head of the board||PH.D.||Medical Biotechnology||Pasteur Institute of Iran|
|Fatemeh Nematpour||The board member||PH.D.||Medical Biotechnology||Pasteur Institute of Iran|
|Saeedeh Ebadat||The board member||PH.D.||Medical Biotechnology||Pasteur Institute of Iran|
|Maliheh Bakhtiyarizadeh||employee||M.A.||Microbial Biotechnology||University of Tehran|
Outlook of Radin Zist Fanavar Company:
Physical development, localization and branding of products.
The company is planning on localizing the process of producing Monoclonal antibody construction cells and aiming the future projects of this company towards producing these cells from the very early stages of the process. It is worth mentioning that these early stage cells are currently being supplied from foreign countries and if the set aims are achieved, the country will become independent in this regard and this will prevent currency outflow. It must also be taken into account that this field has a very high potential for exports and may also lead to currency inflow into the country.
diversification of products and services:
In the future, the company will have some projects in the field of new therapeutic areas from the Cell Therapy of malignant diseases and the production of raw materials for use in the medical, health and cosmetic fields.